Table S2.

Colon biopsies LM-SPM profiles from healthy volunteers and IBD patients

Bioactive metabolomeQ1Q3Healthy tissuesIBD: Focal lesionsIBD: Lesion adjacent
DHA bioactive metabolome
 RvD1375215
 RvD23751750.4 ± 0.211.7 ± 7.83.0 ± 1.0**
 RvD33751470.4 ± 0.40.6 ± 0.31.0 ± 0.8
 RvD53591997.9 ± 3.764.6 ± 45.815.3 ± 6.1
 RvD6359101
 17R-RvD13752330.9 ± 1.0
 17R-RvD3375147
 PD13591530.4 ± 0.21.4 ± 0.90.5 ± 0.2
 10S,17S-diHDHA3591532.7 ± 0.816.8 ± 12.06.1 ± 3.1
 17R-PD13591530.1 ± 0.11.7 ± 1.0*0.3 ± 0.1
 MaR1359221
 7S,14S-diHDHA3592212.1 ± 1.020.5 ± 15.05.9 ± 2.6
n-3 DPA bioactive metabolome
 RvD1n-3 DPA3771430.6 ± 0.20.8 ± 0.50.4 ± 0.3
 RvD2n-3 DPA37726123.6 ± 21.14.0 ± 1.53.8 ± 1.5
 RvD5n-3 DPA3612631.5 ± 0.76.4 ± 1.0*5.6 ± 2.0*
 PD1n-3 DPA3611830.3 ± 0.10.9 ± 0.1*0.2 ± 0.1
 10S,17S-diHDPA3611830.5 ± 0.34.5 ± 3.11.4 ± 0.2*
 MaR1n-3 DPA3612490.6 ± 0.30.7 ± 0.42.8 ± 2.0
EPA bioactive metabolome
 RvE13491612.6 ± 2.3
 RvE23331156.2 ± 2.59.4 ± 4.86.5 ± 3.8
 RvE33332010.1 ± 0.10.2 ± 0.2
AA bioactive metabolome
 LXA43512171.3 1.00.5 0.5
 LXB435122110.7 ± 2.651.2 ± 29.19.9 ± 4.7
 5S,15S-diHETE33523534.6 ± 12.2123.1 ± 58.052.9 ± 23.4
 15R-LXA43511154.8 ± 2.012.4 ± 5.1#3.0 ± 1.4
 15R-LXB4351221
 LTB43351957.5 ± 2.842.3 ± 29.47.2 ± 2.3
 20-OH-LTB435119510.5 ± 6.5*2.9 ± 2.4
 PGD2351189187.9 ± 45.7341.7 ± 95.8185.0 ± 37.8
 PGE2351189349.8 ± 110.81850.5 ± 899.9*364.6 ± 145.1
 PGF35319368.4 ± 28.182.3 ± 20.843.4 ± 14.8
 TxB236916966.4 ± 11.8183.5 ± 41.7**#74.7 ± 29.2
  • Lipid mediators were profiled using an LC-MS/MS based techniques (SI Materials and Methods). Q1, M-H (parent ion) and Q3, diagnostic ion in the MS-MS (daughter ion). Results are expressed as pg/10-mg tissue; mean ± SEM, n = 11 healthy tissues, n = 9 IBD–Lesion adjacent biopsies, and n = 10 IBD–Focal lesion biopsies. Results are expressed as pg/10-mg tissue. *P ≤ 0.05 and **P ≤ 0.01 compared with healthy tissues; #P ≤ 0.05 compared with IBD–Lesion adjacent biopsies. The detection limit was ∼0.1 pg. A dash (—) represents below limits of detection.